Floatz logo

Leucine

Corticobasal Degeneration Disorder

Washington University School of MedicineSmall moleculeUnknownDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Corticobasal Degeneration Disorder cohort.

Asset / SponsorPhaseRating
Lithium, Elemental
Westat
Phase 1/2CCC
Davunetide
University of California, San Francisco
Phase 1CC
Gosuranemab
University of California, San Francisco
Phase 1CC
Pittsburgh Compound B Unlabelled
Mayo Clinic
UnknownD
Flortaucipir
Mayo Clinic
UnknownD
ER-176
Mayo Clinic
UnknownD

Same molecule, other indications

Leucine is also rated in:

obesity disorderDormant
CC
Indicative · Phase 2
46 / 100
View asset →
Alzheimer diseaseDormant
D
Indicative · N/A
30 / 100
View asset →
hyperglycemiaDormant
D
Indicative · N/A
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →